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The Role of the Clinical Nurse Leader in Reintroducing and Sustaining a Successful
Cancer Risk Assessment Program in a Community Hospital Setting
With the advancements in cancer genetics and risk identification of both familial
and genetically predisposed individuals, the importance of integrating risk stratification
into practice is more important than ever. While some patients may not be able to avoid
an inevitable cancer diagnosis, understanding risk can enhance adherence to lifestyle
changes, screening practices, and even prophylactic prevention strategies.
The American Cancer Society (ACS) has amended current guidelines concerning
the screening and treatment of women at average risk for breast cancer to begin yearly
screening mammograms at age 45 (as cited in Oeffinger et al., 2015). The opportunity to
screen beginning at age 40–44 is optional based on self-determination and consult with a
physician, at which point the recommendation of annual mammography is based on the
level of cancer risk for the individual. However, evidence demonstrates that of 90% of
women who qualified as “high risk” for consideration of BRCA testing [as defined by the
United States Preventative Services Task Force (USPSTF)] that shared this information
with their primary care provider, only 20% were referred for genetic counseling (Cragun
& Pal, 2013). This indicates that significant portions of the population that may be at
increased risk are unidentified, and many clinicians in primary care are unaware of the
familial characteristics that denote an individual as high risk. A 2012 study states that
women as young as 25 who are known to have a BRCA mutation are recommended to
begin screening mammography annually (Pal & Vadaparampil, 2012), an age far outside
of the parameters recommended by the ACS. For individuals who may not be aware of
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their risk and are following recommendations based on ACS guidelines, screening may
be commencing later than it should.
Second to age, a strong family history of cancer diagnoses is the most significant
indicator of determining an individual’s risk for development of the disease (Amir,
Freedman, Seruga, & Evans, 2010) and hereditary conditions account for roughly five to
10% of all cancers, increasing an affected individual’s risk of developing cancer in their
lifetime over the general population (“Integrating Genetic”, 2008). Amir et al. (2010) go
on to state that even without an identified genetic mutation, those individuals who present
with an increased 5-year risk of developing breast cancer, based on family history
algorithmic risk assessment models, benefit from enhanced screening, lifestyle changes,
and preventative pharmacological and/or surgical interventions. The incentive, then, is to
pursue prevention as well as curable detection; earlier diagnosis and staging that
increases treatment options and improves prognosis (Caplan, 2014). Since individuals
that may be susceptible to the development of cancer due to hereditary factors do not
present with phenotypic clues, the importance of obtaining a comprehensive family
history is the first step in identifying high-risk patients. Therefore, reinstating a
comprehensive cancer risk assessment (CRA) program within the community-based
breast center will potentially increase the rate of identification of moderate to high-risk
patients leading to improved outcomes.
Clinical Leadership Theme
The most appropriate theme for the Clinical Nurse Leader (CNL) role in the
development of this project is Care Environment Management. Embedded within this
curricular element is the CNL role of Team Manager, which the CNL will demonstrate
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by identifying both clinical and financial outcomes that improve patient safety, timeliness
and quality of care, as well as improving efficiency and appropriateness of care delivery
thereby increasing downstream revenue for the organization.
Statement of the Problem
In light of primary care provider lack of knowledge in adequately identifying
moderate to high-risk cancer patients, a comprehensive CRA program would serve to
identify such patients as well as provide clinician education on cancer syndrome
characteristics. A previously grant funded CRA program within the microsystem was
able to provide this service, but has subsequently been terminated due to institutional
factors. This has led to a sharp decline in the number of patients identified and
appropriately referred for services to manage their individual risk.
Project Overview
The project goal of reinstating the CRA program, with the intent to analyze and
overcome barriers that led to the elimination of the previous program, will be to close the
gap in at-risk patient identification and ensure proper implementation and sustainability.
This will demonstrate benefit both to the community as well as the institution by
potentially decreasing the impact of late stage cancer incidence while simultaneously
setting the institution apart as a unique provider of such services and increasing
downstream revenue. The project deliverable will be a comprehensive analysis of the
program, which will be presented to both clinical and administrative stakeholders in
August 2017. This analysis will include the presentation of current evidence to
demonstrate the validity and need of CRA within the setting, a cost-benefit analysis of a
new CRA program, and multiple staff infrastructure alternatives at each stage (initial

CNL ROLE IN CANCER RISK ASSESSMENT

5

staffing needs with additional staff added in accordance with program growth), as well as
recommendations for implementation. The specific aim at this stage of project
development is to demonstrate evidence that incentivizes each stakeholder to approve the
program implementation. This is a critical element required to achieve the global aim of
increasing identification, stratification, and appropriate referral pathways for patients
within the community that are at moderate to high-risk for genetic or familial cancer
syndromes.
Rationale
Within the microsystem evaluated for this project, a community-based breast
cancer clinic, a previously grant-funded cancer risk assessment and genetic evaluation
(CRA/GE) program led by a Nurse Practitioner-Genetic Counselor (NP-GC) was
analyzed. A review of historical data from the program indicates that the NP-GC was
able to identify and consult with 2,679 patients (an average of 446.5 each year) over the
program’s six-year run (Mott & Coleman, 2015). Of this population, 230 patients
underwent genetic counseling and 12 patients presented with genetic mutations from
subsequent testing. With the conclusion of grant funding in 2014, the program was
unsustainable due to lack of resources; human, financial, and time and the current
program is primarily a referral-based genetic evaluation clinic. In 2015, the program
received 340 referrals resulting in 221 consultations, indicating a 50% decrease in highrisk consultations. This represents the gap in care that was previously provided and the
evidence of the need for the project.
Additional data analysis includes a current microsystem assessment using the
Dartmouth Institute Clinical Microsystem workbooks, assessing the 5 Ps (purpose,
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patients, professionals, processes, and patterns), a SWOT analysis (Appendix A), and
stakeholder interviews, all of which were evaluated to conduct a root-cause analysis to
identify causes for previous lack of sustainability and potential barriers to future
implementation (Appendix B).
Cost Analysis
The projected costs associated with the program are primarily related to staffing.
Several possibilities will be presented, with the best option for the institution to be
determined by the stakeholders. The first cost decision will be to determine if an RN or
an NP should direct the program. The average salary for an RN in the organization is
$50.00 per hour with an annual salary of $104,000 plus benefits [add the industry average
of 30% of salary ($31,200) + $104,000 = $135,200]. The average salary for an NP is
$63.00 per hour with an annual salary of $131,040 plus benefits for a total of
$170,352.00 (P. Olson, personal communication, June 20, 2017). An important fact to
remember during the decision making process is that an NP has the ability to bill for their
services, thereby offsetting the cost of salary.
Since the program will not necessarily require a 1.0 FTE at the outset, based on
historical patient volume data from the previous CRA program, the program would only
require a 0.4 FTE. This translates to the part-time reimbursement rate (not including
benefits) of $41,600 and $52,416 for the RN or NP, respectively. This may be the most
cost-effective way to implement the program with the intent to add additional hours
and/or support staff as the program grows. However, anticipating that it may be difficult
to recruit a quality candidate for a part-time position that is complex in nature, two
possible solutions justify the hiring of 1.0 FTE. If an RN fills the position, the additional
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time outside of what is required for the CRA program could be used in the role as nurse
navigator for patients that have been referred for breast biopsy within the breast-imaging
center. This would involve patient outreach at time of scheduling, pre- and post- biopsy
education, delivery of test results, and hand off to the appropriate clinician. Currently,
this is a role that is not fulfilled within the breast-imaging department and therefore is not
meeting the standard of practice (American College of Surgeons: Commission on Cancer,
2016).
If an NP directs the CRA program, this clinician could fulfill the navigator
position within breast imaging as well as assist within the cancer survivorship program
by working alongside the MD in navigating treatment for all patients stratified as highrisk not appropriate for genetic counseling. As previously mentioned, the NP would also
have the ability to bill for consult and navigation services, increasing the potential for
increased revenue. Each of these options is outlined in further detail in the cost-benefit
analysis (Appendix C). Additional costs consist of education and training expenses,
genetics and survivorship provider time, office supplies, software upgrades, and a
computer.
Methodology
Recommendations will be made to the stakeholders for program implementation,
regardless of the staffing choice that is made. Identification of the appropriate change
theory as well as anticipatory cycles of the Plan, Do, Study, Act (PDSA) model will be
addressed here.
This model chosen to guide the stages of this project has been based on Rogers’
diffusion of innovation. The five-step process Rogers outlined by which change occurs
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recognizes the reversible nature and evolution of the change, as opposed to Lippitt’s
theory, which emphasizes the actions of the change agent rather than the change (as cited
by Sullivan, 2013). The five steps described in Rogers change theory, as cited by
Kaminski (2011), begin with the knowledge or awareness of the individual or group to
the potential new innovation. From there, the second step is where interest is generated
and information gathering begins in order to inform and encourage participation of
stakeholders in the change being considered. Based on evaluation of the data, the third
step is then to make the decision of whether or not to implement the change by
envisioning the impact in the particular setting. It is at this stage that the CNL will
present findings to the stakeholders. The fourth step is the actual implementation of the
innovation followed by the fifth step of confirming the effectiveness of and adoption of
the change. The fourth and fifth steps will be outlined below.
The CRA program will be physically situated near the breast-imaging center,
which is one floor down from the breast cancer center. This is also the site of the previous
CRA program. The nurse director of the program will initially undergo facility and
program-specific orientation as well as guided training from the genetics and
survivorship programs. Upon completion of training, implementation will begin with the
nurse director soliciting patient involvement, with the defined goal of 5 new patients, in
risk assessment from the patient population within breast imaging. The goal of this initial
phase, defined as the first week of the program, is to establish the nurse director’s
competency in risk stratification and subsequent appropriateness of referral. Additionally,
this time will be trialed to establish workflows to facilitate patient tracking and follow-up,
as well as ensure smooth implementation of system software. This will be the data
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evaluated (either success or failure) to move into the next PDSA cycle. The next oneweek cycle, assuming data points indicated success in the first cycle, will be for the nurse
director to intake 5-10 new patients from within breast imaging. In each of these phases
the director will establish contact with each patient and initiate further risk assessment
and patient/family history utilizing the software currently in use by the genetics program.
The goal of this cycle will be for the director to successfully triage each referral to either
the primary care provider for enhanced screening recommendations, genetics, or
survivorship. The data evaluated will be the accuracy for which each recommendation is
made.
After this initial implementation phase, the director will be announced to the
medical group, as well as external referral sources, as the point of contact for all future
risk assessment. In addition to this patient source, the director will continue to solicit
interest from the patient population within breast imaging for additional program
participation. Successful growth has been demonstrated through this method by the
previous CRA program. Long-term data that will be evaluated to determine sustainability
of the program is the percentage increase in; identification of moderate to high risk
patients; the use of screening, diagnostic, and surgical procedural interventions; as well as
the tracking of individual patient data that signifies follow up and continuity of care. This
data is valuable as it demonstrates increased downstream revenue generation from the
program and increased retention of patients within the medical group. Each of these
metrics will be documented at the program start date as well as at the 3, 6, and 12 month
post-implementation dates for comparison and program growth rate.
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Data Sources
Microsystem Assessment
The microsystem assessment was conducted using a modified workbook as
provided by the Dartmouth Institute Clinical Microsystems Assessment tools. This initial
evaluation is critical in understanding the 5Ps of the breast cancer center; purpose,
patients, professionals, processes, and patterns in order to plan and design a CRA
program that fits into existing clinical patterns and workflows. This is particularly
appropriate for this project due to the fact that a previous, similar program has existed in
this setting and as such, the current stakeholders may be subject to experiential bias as to
how the program should be designed or, in some cases, if it should be implemented at all.
This stakeholder bias may also inhibit understanding of current processes and their
evolution since the ending of the previous program.
Institutional Data
In order to accomplish the goal of demonstrating downstream revenue, the CNL
student compiled a list of screening, diagnostic, surgical, and consultative services that
pertain to cancer risk assessment with the assistance of the NP-GC preceptor. This list
was then submitted to the coding department of the medical group to obtain the net
reimbursement rates for each CPT coded procedure. This data will be compared against
the historical data from the previous CRA program, specifically the volume of patients
that would have been appropriately referred for each procedure. This will demonstrate the
potential increase in volume and revenue, thereby offsetting the cost of the program.
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Informational Interviews
Initial informational interviews were conducted a year ago during the first
microsystem assessment. Additional interviews are being conducted as several changes
have occurred within the organization such as a merger with Providence Health. This was
deemed necessary to ascertain any shift in position from the stakeholders over the
passage of time or change in organizational priorities.
Literature Review
According to the Community Health Needs Assessment for Sonoma County
2013-2016, cancer is the leading cause of death for years 2008-2010 and is significantly
higher than the California rate as well as the Healthy People 2020 target (Sonoma
County, 2016). The report also indicates that not only does Sonoma County have a higher
incidence rate than that of the state in all cancers, the specific cancers with the highest
incidence rates are breast and prostate. This highlights the need, very specifically for this
community, for enhanced assessment and screening of genetic and epigenetic cancers.
While the education and active involvement of primary care providers in
identifying characteristics of familial cancer risk is an important and long-term goal, the
evidence is also clear in indicating the need for the integration of a comprehensive CRA
program to be managed by a professional and clinically competent practitioner. Providers
oftentimes are not aware of the risk indicators within a patient history that warrant further
assessment, ultimately resulting in the delay of appropriate patient risk stratification and
intervention. Conversely, with the increasing availability and decreasing costs of large
panel genetic tests, some providers take it upon themselves to order genetic testing

CNL ROLE IN CANCER RISK ASSESSMENT

12

without conducting pre-and post-test counseling as well as not having a full
understanding of the results. This leads to more confusion, anxiety, and mistrust from the
patient.
Two studies included in this review address the impact of delays in detection,
diagnosis, and treatment of cancers and the outcomes of tumor staging and survivability.
Two articles address the overuse of genetic testing, factors that affect benefits and harms
of CRA, and provide evidence to promote the use of qualified risk assessment/genetics
providers. A fifth article outlines a model of incorporating genetic cancer risk assessment
in regions that do not have access to a genetic counselor by partnering the communitybased medial group with City of Hope’s Cancer Screening and Prevention Program
Network (CSPPN). The final item in this review is a PowerPoint presentation given by
the NP-GC and the CNL student’s USF advisor which outlines the data pertaining to the
initial CRA/GC program and is included based on it’s relevance to actual evidence as it
applies to the microsystem setting.
Delays in Care
In the first article, Cragun & Pal (2013) identify a delay as the lack of the primary
care provider’s ability to properly identify high risk patients and provide timely referral
to risk assessment and counseling. The authors highlight the need for OB/GYN providers
to become proficient in identifying the risk indicators present within patient personal and
family histories in order to increase timely referral to enhanced risk assessment and
screenings. The second article, a literature review, Caplan (2014) describes delays in
diagnosis and treatment as attributable to either patient delays (seeking care) or system
delays (providing care). The focus of the review is to determine the difference in tumor
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staging and prognosis in the event of either cause of delay. The findings are mixed and an
important factor is discussed for the heterogeneity of results: the biological characteristics
of the tumor, whether it is large and palpable or slow-growing, may have more to do with
outcomes as this presents both the patient and clinician with an identifiable cancer
symptom. This underscores the importance of weighing personal and family history in
the event that a patient could be at risk and possibly just asymptomatic.
Evidence for the Use of CRA and Genetics Specialists
Nelson et al. (2014) conduct a systematic review of current literature published
from 2004 to 2013 to update the 2005 United States Preventative Services Task Force
(USPSTF) recommendations for women at high risk for BRCA1 and/or BRCA2
mutations and referral for genetic counseling. The authors analyzed the benefits and
harms of risk assessment, genetic counseling and subsequent testing, and preventative
therapies as they pertain to patient perceptions of risk, anxiety, and depression. The
benefits and harms varied relative to risk and the authors go on to state that due to the
complexity of the process at every stage, the service of risk assessment and referral must
be highly individualized to minimize adverse outcomes such as inappropriate over
screening, false positives or negatives, and unnecessary worry or anxiety based on
inconclusive genetic test results or interpretation.
In a similar study, Walker, Licqurish, Chiang, Pirotta, and Emery (2015)
conducted a review of 11 randomized control trials of CRA tools to determine the impact
they have on clinical utility, screening behaviors, and patient perceptions. Results of the
review indicated that the use of risk assessment tools did show a benefit in improving
patient perception of risk; intentions to undergo cancer screenings, and lifestyle changes,
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the actual evidence of behavioral changes were not present. This study indicates the need
for dedicated clinician interventions to conduct follow up surveillance on high-risk
populations to promote enhanced cancer screening behaviors. Both of these studies
highlight the importance of utilizing a trained clinician in risk assessment and genetics
when attempting to incorporate a comprehensive CRA program.
Overcoming Lack of Access
The microsystem that is the focus of this project is fortunate to have a certified
genetic counselor already in place as a resource. This is not always the case, particularly
in the rural community setting. However, location does not negate the need for
specialized clinicians, nor does it prohibit the establishment of a program without this
resource on site. MacDonald, Blazer, and Weitzel (2010), members of Clinical Cancer
Genetics Division at the City of Hope Comprehensive Cancer Center, give detailed
approaches toward implementing genetic cancer risk assessment programs into the
community-based setting. By detailing a delivery model based on partnering a
community-based medical center with an academic institution for technical and
professional support, the authors provide recommendations for expanding the knowledge
of City of Hope into more rural environments.
Microsystem Site-Specific Evidence
Evaluation of the data from the previous CRA/GE program (Mott & Coleman,
2015) demonstrates the impact of the program through a community outreach model of
patient participation and risk identification. Over the 5 year period of active risk
assessment, the program director was able assess 10,522 patients and provide follow up
consultation with 2,679 individuals. This illustrates the volume of patient capture that is
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generated from active patient engagement, not taking into account the potential
percentage increase through a long-term program goal of primary care provider outreach
and education.
Timeline
The project, with it’s newly defined deliverable, will come to fruition over the
months of June, July, and early August 2017 (Appendix D). Due to institutional
constraints in implementing the actual CRA program, the project focus has shifted to one
in which the business case for the program will be presented as this is more in line with
the CNL program deadlines. The success of the deliverable will be measured by the
decision of the stakeholders to move forward with the recommended next steps of
program adoption.
The evaluation of the original microsystem assessment will be conducted to
determine if any significant changes have occurred in the setting from the time of the first
assessment. Informational interviews will then be conducted as a data source. Next, the
CNL student will construct a procedural list with corresponding CPT codes and
reimbursement rates which will then be compared against patient data from the previous
CRA program to establish potential downstream revenue. A cost-benefit analysis will be
generated using staffing data from the organization’s human resources department and
the projected revenue stream previously mentioned. This will then culminate in the
creation of a business plan and PowerPoint presentation to be presented to the
multidisciplinary stakeholders during the first week of August.
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Expected Results
This program has been one that the clinicians within the breast center have
wanted to reimplement since it was originally phased out in 2013. The level of buy-in
from this group, therefore, was assumed at the outset of planning stages and taken into
consideration when deciding how best to design and implement a new CRA program.
During the first round of informational interviews that were conducted in the summer of
2016, the enthusiasm and almost impatience of the clinical stakeholders was evident.
Based on perspectives from this group, it was hard to understand why this had been met
with such institutional inertia. In that same time period, informational interviews were
also conducted with two administrative stakeholders; the director of imaging, and the
area director of operations for the medical group. Both of these meetings shed a
significant amount of light on the source of resistance to a new CRA program.
The director of imaging oversees the radiology department within the hospital as
well as the outpatient breast-imaging center located in the same building as the breast
center. During it’s first incarnation, the CRA program was housed within breast imaging
and conducted by the NP-GC. The program was launched with the design to solicit
patient participation through the mammography clinic by having the patient fill out a
tablet-based questionnaire, given by the mammography staff. The program itself was
successful, however, due to lack of clarity of assigned roles and responsibilities, the
imaging staff felt burdened by the additional work. Add to this personality conflicts and
assumptions of willing participation and the environment became toxic. This was all
explained to the CNL student by the imaging director only after the student had assured
him that his frank honesty would help in the evaluation of potential impacts of the
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program and how best to laterally integrate in the future. In a subsequent meeting with
this same individual conducted on June 20th, 2017, a revised proposal was made of the
integration of a new role, that of the RN or NP CRA director, within his department to
oversee the CRA program as well as fill the gap in current patient-centered care by acting
as the nurse navigator for breast biopsy patients.
The second administrative stakeholder interview involved the area director of
operations (ADO) whose oversight is of the medical group service line. It was clear
during this meeting that the ADO was very aware of the breast clinicians’ desires to bring
back the CRA program, however, the structure of any communication had been siloed
between vested parties. Clinical stakeholders did not effectively communicate their ideas
for methods of implementation nor offer any insights into overcoming conflicts that led
to the erosion of the previous program. With the responsibility to the financial health of
the medical group, the ADO could not see the benefit of resurrecting a program that does
not increase the bottom line. In addition to this, the ADO feels that the NP-GC should be
able to see more patients during the day and argues that the CRA program will only serve
as a feeder for the genetics program, which he believes is already overwhelmed.
The outcomes of theses two interviews have had the most impact on the direction
and planning of this project. By taking what the director of imaging shared and offering
him solutions to the conflicts he had to mitigate from the first program, the second
meeting was very productive. By proposing the solution of a shared FTE with the design
of the infrastructure to grow along with the program and presenting a cogent plan, the
director expressed optimism for the program moving forward. The director gained
additional confidence when the program design was explained to be a stand-alone CRA
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clinic, which would not place his staff in direct contact with the individuals with whom
original conflict had arisen. After the interview with the ADO, insight was gained as to
how best to offset expense in the beginning stages of the program and provided
inspiration to delve deeper into potential revenue sources for the program as well.
As the evidence to the benefits of a CRA program on clinical outcomes is
abundant, there can be no argument against the implementation based on its virtues of
patient-focused care. However, good intentions and clinical improvements can be
derailed if not properly introduced and managed. By acting as the liaison between the
vested parties, the CNL was able to listen to concerns and priorities and integrate the
shared and individual values in the design and focus of the project. It is for these reasons
that the expected outcome is to be one of adoption and forward momentum of the
program implementation.
Nursing Relevance
The tools required to effectively evaluate a quality improvement project in the
clinical setting are numerous. The nurse must have the clinical knowledge to assess
where a gap in care exists, as well as to determine the interventions that will potentially
improve outcomes. Secondarily, the nurse must be able to objectively evaluate the
environment including setting, culture, habits, and external influences, to determine if the
project will be feasible in that location at that time. In other words, even with the best
intentions not all projects are a good fit in every microsystem.
The elements of this project are two-fold. The first is the element of increasing the
knowledge base within the contexts of hereditary and family history as it pertains to
cancer risk. Improving the understanding in all nurses, regardless of specialty, of the
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hallmark characteristics within a patient’s personal or family history that indicate
potential increased risk facilitates the earlier assessment, identification, and appropriate
intervention for each individual. As nurses are oftentimes the frontline clinicians that
conduct extensive histories, this increased level of awareness could help to mitigate
disease incidence as well as increase curable detection, which often leads to greater
treatment options and more favorable prognoses.
The second element is that of objective auditing. This role is critical in expanding
the credibility of the nurse, as it requires the objective evaluation of the feasibility of an
improvement being considered and removing bias based on emotion or passion. It is one
thing to see where there is a gap in care and have the evidence-based solution ready to
roll out, but if the nurse lacks the ability to identify all the stakeholders at each level of
involvement, recognize the financial impacts, or assess the climate of the environment
and its readiness for change even the best quality improvement initiative will hit a
proverbial wall. The advancement of nursing involves the ability to expand the scope of
thinking to beyond that of just a front line clinician. The nurse must think in the best
interest of all vested parties; patients, families, staff, organization, and community.
Project Summary
Over the course of a year, the CNL student has revised the original project aim of
the actual reintroduction of a CRA program to a focus of creating a value proposition
with the intent to garner administrative and clinical stakeholder support. The clinical
setting of this evaluation is a midsize community hospital with an accredited cancer
program and breast center and affiliated medical group/provider network. Since 2016, the
CNL student conducted a microsystem assessment and developed an action plan to
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reintroduce a CRA program in a clinically complex and politically challenging work
environment.
After completion of initial microsystem and previous CRA program assessments,
the methods for the future program valuation include several diverse data sources. A
literature review of similar program establishment was conducted to determine the
infrastructure needs and develop a proposal which addressee and overcomes the
personnel and logistical issues related to the first CRA program. A patient pathway
flowchart was created to differentiate between the future CRA program, the current
Genetic Evaluation and Management practice, and the Survivorship program (see
Appendix E).
A comparison of historical CRA volume to the current patient volume within the
Genetic Evaluation and Management program revealed a roughly 50% decrease in
potential high-risk patient capture. The CNL student compiled a list of relevant screening
and diagnostic procedural codes and associated Medicare net reimbursement rates, which
were then applied to the potential patient volumes to determine estimated downstream
revenue. Organization market share (30%) was applied to population data related to highrisk indicators to demonstrate additional sources of potential revenue. Personal
communication with the organization human resource department was conducted to
determine future program clinician and clerical staffing reimbursement rates. This data
was applied to the standard benefits rate of 30% to calculate staffing infrastructure costs
which, along with orientation and training expenditures, were then added to capital
expenditures to create estimated program expenses. Information from both data sets was
used to create an Initial Financial Impact Analysis (see Appendix F).
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Conclusion
The reintroduction of a comprehensive CRA program within this clinical setting
will add value to the community hospital and the medical group/provider network as well
as enhance the level of patient/family centered care. The recommendation to the
organization, based on data evaluation, is to conduct a complete financial analysis and
business plan within a shared partnership, funded equally by the medical group and the
hospital.
To restate, the clinical value on quality outcomes of a program such as this is not
the subject of debate. Rather, due to lack of interdepartmental communication, biases,
and shifting clinical and organizational priorities the benefits of a future CRA program
became undermined by the siloed nature of conflicting values. The requirement became
to inject into the setting an advocate of the program and it’s outcomes with the intent to
objectively assess the environment and it’s readiness for change; culturally, logistically,
and financially. The role of the CNL student in this capacity has resulted in the
demonstration of a valuable resource. The CNL student has been able to perform as
patient advocate, systems and risk analyst, and outcomes manger, as well as a facilitator
of communication to understand and verbalize common goals.
In spite of the evolution of this project from a tangible program implementation to
that of a value proposition, the shifting focus of this project highlights the dynamic nature
of the health care environment. The skills learned by the CNL student have been in a real
world context, with far reaching application toward future endeavors.
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Appendix B
Root Cause Analysis
Fishbone Diagram

People

Process
End of grant funding led to shift in

Single clinician (NP-GC) to

clinician function priorities

manage CRA program

Limited staff infrastructures resulting

Site staff unclear on

in inability to conduct pt. follow up

their role in program
MA functions primarily
in clerical role

Pt. volume increases led to GC
inability to maintain CRA

Lack of designated space
Site staff resentful of increased
duties with no input

to grow program
Merger with SJH – shift in
priorities and structures

Lack of interdepartmental
support of program

Environment

Site

Elimination of the
Cancer Risk
Assessment Program
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Appendix C
Cost-Benefit Analysis
Cost Item

Part-Time
0.4 FTE

Staffing
Salary
Benefits
Training
Staffing Subtotal
Survivorship/GC provider time
Office Supplies
Software
Hardware
Startup Subtotal
Total

RN
NP
$41,000.00
$52,416.00
N/A
N/A
$1,000.00
$1,000.00
$42,000.00
$53,416.00
$3,000.00
$1,000.00
$1,500.00
$4,000.00
$9,500.00
$51,500.00
$62,916.00

Full-Time (Incorporates Nurse Navigator Role)
1.0 FTE
RN
NP
$104,000.00
$131,040.00
$31,200.00
$39,312.00
$1,000.00
$1,000.00
$136,200.00
$171,352.00
$3,000.00
$1,000.00
$1,500.00
$4,000.00
$9,500.00
$145,700.00
$180,852.00

Benefit Item
Increased early detection and diagnosis in patients of first or second cancers
Increased identification and stratification of patients at risk for hereditary or sporadic cancer
Increased treatment options in identified patients resulting in prevention and/or curable detection
Increased patient volume into the organization by offering a comprehensive cancer risk assessment program
*Increased downstream revenue related to enhanced screening/diagnostic/surgical procedures
Increased patient satisfaction and retention related to concurrent implementation of the nurse navigator role in breast
biopsy
*Cost offset through the use of a Nurse Practitioner in the new role through clinician billable time

*Indicates benefit items quantified within the Initial Financial Impact Analysis (see
Appendix F)
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Appendix D
Gantt Chart Timeline
May 29 – August 12, 2017
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Running head: PROSPECTUS
Appendix E
Recommended Patient Flowchart – Future CRA Program

PROSPECTUS
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Appendix F
Initial Financial Impact Analysis

